Antibacterials: a dying trade

Antibacterials: a dying trade
: Despite strong worldwide demand for effective antibacterial products, sustaining growth within this segment will become a challenging task for major pharmaceutical companies. Currently only six marketed drugs have sales of greater than $1 billion and by 2011, 12 out of 29 key products will face patent expiry. A relatively sparse R&D pipeline will do little to replace older products.


Comments are closed.

Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog